FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

The agency said it will review Merck and Schering Plough Pharmaceuticals' recent trial once the FDA receives the final study results on the drug, which is a combination of Zetia (ezetimibe) and Zocor (simvastatin) in one tablet.

Merck and Schering Plough last week released data showing that the combination drug failed to slow progression of heart disease better than Zocor, which is less expensive.

The FDA said that study was not designed to detect any difference in risk of having a heart attack or stroke between the two treatments. The agency said an ongoing trial is designed to evaluate the effect of Vytorin versus Zocor on heart disease and stroke.

Merck issued a statement Friday in support of the the controversial clinical trial. "We stand behind Vytorin and Zetia and stand behind our science that has brought these cholesterol-lowering medications to millions of people around the world," Peter S. Kim, president of Merck Research Laboratories, said.

Copyright 2008 by United Press International

Explore further: First device approved for dialysis-related amyloidosis

add to favorites email to friend print save as pdf

Related Stories

Evolving robot brains

9 hours ago

Researchers are using the principles of Darwinian evolution to develop robot brains that can navigate mazes, identify and catch falling objects, and work as a group to determine in which order they should ...

Facebook fends off telecom firms' complaints

9 hours ago

Facebook founder Mark Zuckerberg fended off complaints on Monday that the hugely popular social network was getting a free ride out of telecom operators who host its service on smartphones.

Scientists find clues to cancer drug failure

9 hours ago

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy ...

Glass coating improves battery performance

9 hours ago

Lithium-sulfur batteries have been a hot topic in battery research because of their ability to produce up to 10 times more energy than conventional batteries, which means they hold great promise for applications ...

Recommended for you

FDA launches first app to identify drug shortages

8 hours ago

(HealthDay)—A mobile phone application (app) has been released to identify current drug shortages, resolved shortages, or discontinuations of drug products, according to a press release published by the ...

FDA approves first lower-cost biotech drug (Update)

10 hours ago

Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.

A look at the growing use of synthetic drugs

11 hours ago

In recent years, hundreds of new synthetic recreational drugs have emerged – drugs that neither the general public nor the scientific community know very much about. Many of these new synthetic drugs – ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.